摘要
罕见病,又称"孤儿病",是指发病率极低的疾病,绝大部分属于先天性疾病、慢性病,且常常危及生命。近年来,随着公众认知度的提高、国家政策的支持、诊断及治疗技术的进步,罕见病药物市场逐渐发展起来,销售额逐年增加,出现多个"重磅炸弹"级药物。国际大型药企开始抢占罕见病药物市场并且加紧药物研发,目前正在研发的罕见病药物有500多个,主要针对罕见癌症、遗传性疾病、神经类疾病、传染性疾病和自身免疫性疾病等。发达国家和地区在罕见病管理及市场发展方面都已经比较完善,而中国在这方面还比较落后。对中国罕见病药物市场的发展困境进行了分析并提出了几点建议,希望能够促进国内罕见病药物市场的快速发展。
Rare diseases, also known as ＂orphan diseases＂, refer to the diseases which have a very low morbidity. Most of orphan diseases are congenital disease or chronic disease, and they are often dangerous. With the improvement of public awareness, support of national policy and development of diagnosis and treatment technology, orphan drugs market has gradually developed. Sales of the orphan drugs increased year by year and several ＂heavy bombs＂ have arisen. The international pharmaceutical companies began to seize the orphan drugs market and intensified drug development. The number of orphan drugs under research and development is more than 500, which are mainly for rare cancer, hereditary diseases, neurological diseases, infectious diseases and autoimmune diseases. Developed countries and regions have mature management system and market of orphan drugs, but China is still relatively backward in this regard. The dilemmas of domestic orphan drugs market is analyzed and some suggestions for these dilemmas are puted for ward, hoping to promote the development of the domestic orphan drugs market.
作者
李敏
吴日伟
LI Min WU Ri-wei(Food and Pharmaceutical Industry Construction Management Office, Wuhan Airport Economic and Technological Development Zone , Wuhan 430043, China Nanehang National High -Teeh Industrial Development, Nanchang 330096, China)
出处
《中国生物工程杂志》
CAS
CSCD
北大核心
2017年第7期144-150,共7页
China Biotechnology
作者简介
电子信箱：limin2014070I@163．com
